Cabozantinib and atezolizumab for recurrent or metastatic esophageal squamous cell carcinoma after platinum-based chemotherapy failure: a single-arm phase II study and biomarker analysis.

Saved in:
Bibliographic Details
Title: Cabozantinib and atezolizumab for recurrent or metastatic esophageal squamous cell carcinoma after platinum-based chemotherapy failure: a single-arm phase II study and biomarker analysis.
Authors: Kuo HY; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan., Huang TC; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan., Chuang CH; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan., Wu TC; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.; Department of Oncology, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan., Huang YL; Department of Pathology, National Taiwan University Cancer Center, Taipei, Taiwan., Lin CC; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan., Lee JM; Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan., Guo JC; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. jhecyuanguo@gmail.com.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan. jhecyuanguo@gmail.com.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan. jhecyuanguo@gmail.com., Hsu CH; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. chihhunghsu@ntu.edu.tw.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan. chihhunghsu@ntu.edu.tw.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan. chihhunghsu@ntu.edu.tw.
Source: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2026 May 09. Date of Electronic Publication: 2026 May 09.
Publication Type: Journal Article
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1432-0851
DOI:10.1007/s00262-026-04408-w